Dermata Therapeutics(US:DRMA)2025-11-14 21:05Strategic Direction - Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care treatments, with plans to launch its first OTC product, a once-weekly acne kit, in mid-2026[1][3][10]. - The company plans to sell the acne kit directly to consumers, estheticians, and dermatologists for in-office treatments[3][10]. - Dermata is working with a branding agency to create a unique brand identity for its new OTC product portfolio[10]. Financial Performance - As of September 30, 2025, Dermata had $4.7 million in cash and cash equivalents, an increase of $1.5 million from $3.2 million as of December 31, 2024[5][12]. - The net loss for the quarter ended September 30, 2025, was $1.7 million, compared to a net loss of $3.2 million for the same period in 2024[14]. - The total operating expenses for the quarter ended September 30, 2025, were $1.8 million, down from $3.2 million for the same period in 2024[14]. - Dermata expects its current cash resources to be sufficient to fund operations into the second quarter of 2026[5]. Research and Development - Research and development expenses decreased to $0.5 million for the quarter ended September 30, 2025, down from $2.4 million for the same period in 2024, primarily due to reduced clinical expenses from the XYNGARI™ STAR-1 acne study[6][14]. - Dermata's XYNGARI™ Phase 3 STAR-1 clinical trial for moderate-to-severe acne met all three primary endpoints, showing statistically significant results versus placebo[3]. Operating Expenses - Selling, general and administrative expenses increased to $1.3 million for the quarter ended September 30, 2025, compared to $0.8 million for the same period in 2024, driven by higher marketing expenses[7][14].